| pubmed-article:8402504 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8402504 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8402504 | lifeskim:mentions | umls-concept:C0432487 | lld:lifeskim |
| pubmed-article:8402504 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:8402504 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8402504 | pubmed:dateCreated | 1993-11-10 | lld:pubmed |
| pubmed-article:8402504 | pubmed:abstractText | Posttransplantation lymphoproliferative disorders after solid organ transplantation are a serious complication occurring in 1-10% of patients. Different therapies have been used, but the optimal treatment is unknown. There is relatively little information in the literature on the experience with cytotoxic chemotherapy. | lld:pubmed |
| pubmed-article:8402504 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8402504 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402504 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8402504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402504 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8402504 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8402504 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8402504 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:SmithC RCR | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:GarrettT JTJ | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:BarrM LML | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:RostE RER | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:DrusinR ERE | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:SchulmanL LLL | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:ChenJ MJM | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:ChadburnAA | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:MichlerR ERE | lld:pubmed |
| pubmed-article:8402504 | pubmed:author | pubmed-author:ReisonD SDS | lld:pubmed |
| pubmed-article:8402504 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8402504 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8402504 | pubmed:volume | 72 | lld:pubmed |
| pubmed-article:8402504 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8402504 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8402504 | pubmed:pagination | 2782-5 | lld:pubmed |
| pubmed-article:8402504 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:meshHeading | pubmed-meshheading:8402504-... | lld:pubmed |
| pubmed-article:8402504 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8402504 | pubmed:articleTitle | Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. | lld:pubmed |
| pubmed-article:8402504 | pubmed:affiliation | Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York 10032. | lld:pubmed |
| pubmed-article:8402504 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8402504 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8402504 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8402504 | lld:pubmed |
